LONZA BIOLOGICS PLC

PaymentCheck Score 2025
46Poor
#3865 in UK
#650 in South East

Company Information

Company Number
02742471
Registered Address
228 Bath Road, Slough, Berkshire, SL1 4DX
Status
Active
Employee Count
1,389
Turnover
£266,962,000
EBITDA
£65,074,000

Additional Details

Company Type
Public limited Company
Incorporated On
25 August 1992
Nature of Business
96090 - Other service activities not elsewhere classified
Industries
Coming Soon
Region
South East

Time to Pay

Average Time to Pay
56 days
Shortest Period:0 days
Longest Period:90 days
Max Contractual:90 days

Payment Timeline

Within 30 Days
22%
31-60 Days
68%
After 60 Days
10%
Not Paid Within Terms12%

Payment Features

Participates in Codes✗ No
E-Invoicing✗ No
Supply Chain Finance✗ No

Payment Score History

Excellent (80+) Good (60-79) Fair (40-59) Poor (20-39) Very Poor (<20)

Performance Reports History

Reporting Period Filed: 2025-01-28
Reporting PeriodFiling DateAverage Time to Pay (days)Paid within 30 daysPaid 31-60 daysPaid after 60 daysNot Paid within Terms
01 Jan 2025 - 30 Jun 202530 Jul 20255919%68%13%13%
01 Jul 2023 - 31 Dec 202309 Jan 20244531%65%4%14%
01 Jan 2023 - 30 Jun 202301 Aug 20236024%59%17%25%
01 Jan 2022 - 30 Jun 202201 Aug 20225712%59%29%4%
01 Jan 2021 - 30 Jun 202130 Jul 20215112%61%27%4%
01 Jul 2020 - 31 Dec 202021 Feb 20215514%59%27%6%
01 Jul 2019 - 31 Dec 201904 Feb 20204837%47%16%31%

Payment Time Trends

Payment Distribution Trends

Invoice Payment Practices

This information is as reported by the business, and responses are in their own words.

Payment Terms

Standard payment terms

There are no standard published payment terms for Lonza Biologics PLC, but most contracts are agreed with terms that allow for payment within 31-60 days

Were there any changes to the standard payment terms in the reporting period?

No information available

Any other information about payment terms

No additional information

Maximum contractual payment period agreed

90

Dispute Resolution Process

Invoices which are incorrectly issued, or are issued in opposition to the previous contract agreements or arrangements are rejected by email to the vendor's correspondence address held within Lonza's systems; with accompanying instructions on what should be corrected for the invoice to be accepted. Lonza Biologics also operates a PO policy, where invoices without a Lonza PO are rejected unless specifically agreed in the contract with the vendor.

Other Payment Information

Has this business signed up to a code of conduct or standards on payment practices?

For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.

Does this business offer e-invoicing in relation to qualifying contracts?

This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.

Does this business offer supply chain finance?

This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.

Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?

During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?

No information available

Company Summary

LONZA BIOLOGICS PLC is a leading biotechnology company that specializes in the production of high-quality biological products and services. The company is committed to sustainability and has implemented various initiatives to reduce their environmental impact.

Their sustainability program includes reducing energy consumption, water usage, and waste generation in their manufacturing processes. They also have a strong focus on responsible sourcing and have set targets to increase the use of sustainable materials in their products.

LONZA BIOLOGICS PLC offers a wide range of products and services, including cell and gene therapy products, antibodies, and drug delivery technologies. They also provide contract manufacturing and development services for biopharmaceutical companies.

The key people at LONZA BIOLOGICS PLC include CEO Pierre-Alain Ruffieux, CFO Rodolfo Savitzky, and COO Marc Funk. The company is headquartered in Basel, Switzerland, and has offices and facilities in Europe, North America, and Asia.

To learn more about LONZA BIOLOGICS PLC and their products and services, you can visit their website at www.lonza.com. Their registered office address is Muenchensteinerstrasse 38, 4052 Basel, Switzerland.

Financial Metrics

Cash
£4,937,000
Net Worth
£139,305,000
Total Current Assets
£122,032,000
Total Current Liabilities
£77,151,000

Company Location